4 min read
ASCO 2026: RAS Is No Longer Undruggable
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...
We understand how high the stakes are with gene therapy programs, and that nothing is standard about the study design, study conduct or regulatory process. Join us at the 4th Annual Gene Therapy for Rare Disorders to learn about the manufacturing, clinical, and commercialization challenges drug developers face when bringing gene therapies to market.
Join to hear Veristat discuss our gene therapy expertise across the clinical development pathway including:
.
![]()
February 24, 2021 at 11:30 AM EST
Speaker: Rachel Smith, Project Director, Veristat
Visit the conference website to register or learn more:
4 min read
Jun 15, 2026 Veristat News
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...
10 min read
Jun 12, 2026 Veristat Blog
This May 2026 regulatory update highlights multiple guidances issued by the FDA across cell and gene therapy, clinical...